Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 134 participants.

Also called NCT06141980

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 134 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06141980
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06141980. Allocation not applicable; no masking; primary purpose treatment. Start 2023-12 (anticipated); primary completion 2025-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes Mellitus
Condition
T2DM (Type 2 Diabetes Mellitus)
Intervention (Drug)
DWP16001 0.3 mg
Lead sponsor
Daewoong Pharmaceutical Co. LTD. (class: industry)

Record details

Record id
cardio:ct-nct06141980
Content hash
5f484b03ce92de394b08aad60891e24b13fe5ac4e506e0d49a9615df341e3d1f